查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856952

全球 CRISPR 基因编辑疗法市场：预测至 2032 年—按产品、应用、最终使用者和地区分類的分析

CRISPR Gene Editing Therapies Market Forecasts to 2032 - Global Analysis By Product, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球 CRISPR 基因编辑疗法市场预计到 2025 年将达到 53 亿美元，到 2032 年将达到 144 亿美元，预测期内复合年增长率为 15.2%。

CRISPR基因编辑疗法是一种先进的医疗干预手段，它利用CRISPR-Cas9技术精确地修改生物体的DNA。透过针对特定基因，这些治疗方法可以纠正基因突变、抑制有害基因或引入有益基因序列，从而为遗传性疾病、癌症和病毒感染提供潜在的治疗方法。与传统医疗手段不同，CRISPR疗法旨在从基因层面解决疾病的根本原因。目前的研究重点在于提高CRISPR疗法的精准性、安全性和递送方式，使其成为个人化和再生医学领域的一项革命性技术。

CRISPR平台技术的快速发展

精准编辑工具，例如碱基编辑器和先导编辑器，正在提高标靶准确性并减少脱靶效应。与人工智慧驱动的设计和高通量筛检的结合，正在增强候选药物的选择和检验。开发人员正在为复杂的适应症引入模组化递送系统和多重编辑通讯协定。对平台可扩展性和自动化的投资正在提高可重复性和监管合应对力。这些创新正在推动全球生物技术生态系统的临床应用和产品线扩展。

体内标靶递送的挑战

病毒载体和脂质奈米颗粒在组织特异性、免疫抗原性和有效载荷能力方面面临许多挑战。对于神经系统疾病和代谢性疾病而言，如何穿过血脑障壁并实现全身分布仍然是一大难题。研发人员必须权衡基因编辑效率、毒性和免疫反应控制。在临床试验过程中，监管机构对递送平台的审查力度也不断增加。这些限制持续限制全身性和多器官疗法的发展。

遗传疾病和罕见疾病的兴起

单株疾病，例如镰状细胞贫血症、Duchenne氏肌肉失养症和囊肿纤维化，正在推动早期临床应用。罕见疾病基金会和患者权益组织正在资助转化研究和临床试验招募。监管机构正在为罕见疾病适应症和突破性治疗方法提供快速审批途径。与新生儿筛检和基因组诊断的整合正在提高早期疗育的可能性。这些趋势正在推动对精准基因编辑解决方案的长期需求。

高昂的製造和处理成本

生产符合GMP标准的试剂、载体和细胞疗法需要专门的基础设施和熟练的员工。批次差异和品管的复杂性增加了营运负担和监管风险。一次性治疗药物的定价模式对支付者和医疗保健系统而言仍然不透明。报销框架正在缓慢发展，尤其是在罕见疾病和超罕见疾病领域。这些成本压力持续阻碍商业性可行性和公平取得。

新冠疫情的影响：

疫情加速了对CRISPR技术在诊断、疫苗研发和治疗创新方面的投资。基于CRISPR的检测平台被部署用于快速筛检新冠病毒和追踪变异株。供应链中断影响了试剂可得性，并延缓了基因编辑专案的检测週期。远端协作和数位实验室工具在学术机构和生物技术公司中变得司空见惯。随着CRISPR技术进入主流视野，大众对基因组医学的认知度也随之提升。这些转变正在加速CRISPR技术长期融入全球卫生策略。

预计在预测期内，CRISPR试剂盒和试剂细分市场将成为最大的细分市场。

由于CRISPR试剂盒和试剂在研究、诊断和治疗开发中发挥基础性作用，预计在预测期内，该细分市场将占据最大的市场份额。这些产品包括核酸酶、引导RNA、递送系统和检验工具，广泛应用于学术、临床和商业实验室。市场对高保真度酶、可定製文库和可扩展试剂规格的需求日益增长。供应商提供针对不同细胞类型、生物体和编辑工作流程量身订製的模组化试剂盒。与自动化平台和云端基础设计工具的整合正在提高通量和可重复性。

预计在预测期内，学术和研究机构领域将实现最高的复合年增长率。

预计在预测期内，学术和研究机构领域将呈现最高的成长率，因为大学和公共研究机构正将其 CRISPR 计画扩展到基础科学和转化医学领域。研究机构正推出基因组工程中心、合作联盟和开放取用工具包来加速创新。政府机构和慈善组织的资助正在支持早期和概念验证研究。学术实验室正在推动递送、特异性和多重化方面的突破，并将其转化为商业性产品线。与生物技术公司和合约研究组织 (CRO) 的伙伴关係正在促进临床试验的准备和智慧财产权许可。

占比最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的生物技术基础设施、积极的监管参与以及卓越的学术水平。美国拥有数量最多的CRISPR新兴企业、研究机构和临床试验赞助商。美国国立卫生研究院（NIH）和美国国防高级研究计划局（DARPA）的资助正在支持平台创新以及罕见疾病和复杂疾病的治疗方法检验。美国食品药物管理局（FDA）关于基因编辑疗法的指导正在提高透明度并加快核准。加拿大正在基因组学和再生医学领域拓展转化研究和官民合作关係。这些因素共同推动了北美在基于CRISPR的疗法开发领域的领先地位。

复合年增长率最高的地区：

由于基因组医学、学术投资和转化基础设施的融合，亚太地区预计将在预测期内呈现最高的复合年增长率。中国、日本、韩国和印度等国家正在农业、诊断和人类治疗领域扩大CRISPR研究。政府支持的计画正在资助基因组编辑中心、生物製造中心和临床试验网络。当地企业正在推出针对特定区域、并根据人群遗传学和疾病负担量身定制的治疗方法。学术机构正在发表具有影响力的研究成果，并与全球生物技术领导者合作。

免费客製化服务

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 原始研究资料
    • 二手研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 介绍
  • 司机
  • 抑制因素
  • 市场机会
  • 威胁
  • 产品分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 公司间的竞争

5. 全球 CRISPR 基因编辑疗法市场（按产品划分）

  • CRISPR试剂盒和试剂
  • CRISPR质体载体
  • 设计和客製化工具
  • 基因编辑平台软体
  • 合约开发与生产服务 (CRO/CMO)
  • 基因合成与定序服务
  • 基因表现分析工具
  • 其他产品

6. 全球 CRISPR 基因编辑疗法市场（按应用划分）

  • 治疗研发
    • 罕见遗传疾病
    • 瘤
    • 血液疾病
    • 感染疾病
  • 药物发现与筛检
  • 功能基因体学
  • 干细胞与再生医学
  • 精准医疗/个人化医疗
  • 免疫疗法发展
  • 基因治疗临床试验
  • 药物基因组学
  • 目标检验
  • 其他用途

7. 全球 CRISPR 基因编辑疗法市场（按最终用户划分）

  • 製药和生物技术公司
  • 学术研究机构
  • 医院和专科诊所
  • 政府和监管机构
  • 诊断公司
  • 生物製造公司
  • 其他最终用户

8. 全球 CRISPR 基因编辑疗法市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十章：公司简介

  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Intellia Therapeutics, Inc.
  • Beam Therapeutics Inc.
  • Caribou Biosciences, Inc.
  • Mammoth Biosciences, Inc.
  • Scribe Therapeutics, Inc.
  • Graphite Bio, Inc.
  • Tessera Therapeutics, Inc.
  • eGenesis, Inc.
  • Verve Therapeutics, Inc.
  • Sherlock Biosciences, Inc.
  • Metagenomi, Inc.
  • ToolGen, Inc.
  • Cellectis SA
Product Code: SMRC31816

According to Stratistics MRC, the Global CRISPR Gene Editing Therapies Market is accounted for $5.3 billion in 2025 and is expected to reach $14.4 billion by 2032 growing at a CAGR of 15.2% during the forecast period. CRISPR gene editing therapies are advanced medical interventions that utilize the CRISPR-Cas9 technology to precisely modify an organism's DNA. By targeting specific genes, these therapies can correct genetic mutations, disable harmful genes, or introduce beneficial genetic sequences, offering potential cures for inherited disorders, cancers, and viral infections. Unlike traditional treatments, CRISPR therapies aim to address the root cause of diseases at the genetic level. Ongoing research focuses on improving precision, safety, and delivery methods, making CRISPR a transformative approach in personalized and regenerative medicine.

Market Dynamics:

Driver:

Rapid technological advances in CRISPR platforms

Precision editing tools such as base editors and prime editors are improving targeting accuracy and reducing off-target effects. Integration with AI-driven design and high-throughput screening is enhancing candidate selection and validation. Developers are launching modular delivery systems and multiplexed editing protocols for complex indications. Investment in platform scalability and automation is improving reproducibility and regulatory readiness. These innovations are propelling clinical translation and pipeline expansion across global biotech ecosystems.

Restraint:

Delivery challenges for in vivo targets

Viral vectors and lipid nanoparticles face barriers in tissue specificity, immunogenicity, and payload capacity. Crossing the blood-brain barrier and achieving systemic distribution remain difficult for neurological and metabolic disorders. Developers must balance editing efficiency with toxicity and immune response management. Regulatory scrutiny around delivery platforms is increasing across clinical trials. These limitations continue to constrain progress in systemic and multi-organ therapies.

Opportunity:

Growing prevalence of genetic and rare diseases

Monogenic disorders such as sickle cell anemia, Duchenne muscular dystrophy, and cystic fibrosis are driving early clinical adoption. Rare disease foundations and patient advocacy groups are funding translational research and trial recruitment. Regulatory agencies are offering expedited pathways for orphan indications and breakthrough therapies. Integration with newborn screening and genomic diagnostics is improving early intervention potential. These dynamics are fostering long-term demand for precision gene editing solutions.

Threat:

High manufacturing and therapy costs

GMP-grade production of reagents, vectors, and cell therapies requires specialized infrastructure and skilled labor. Batch variability and quality control complexity increase operational burden and regulatory risk. Pricing models for one-time curative therapies remain uncertain across payers and health systems. Reimbursement frameworks are evolving slowly, especially for rare and ultra-rare conditions. These cost pressures continue to hamper commercial viability and equitable access.

Covid-19 Impact:

The pandemic accelerated investment in CRISPR technologies for diagnostics, vaccine development, and therapeutic innovation. CRISPR-based detection platforms were deployed for rapid COVID-19 screening and variant tracking. Supply chain disruptions affected reagent availability and delayed trial timelines across gene editing programs. Remote collaboration and digital lab tools gained traction in academic and biotech settings. Public awareness of genomic medicine increased as CRISPR entered mainstream discourse. These shifts are accelerating long-term integration of CRISPR into global health strategies.

The CRISPR kits & reagents segment is expected to be the largest during the forecast period

The CRISPR kits & reagents segment is expected to account for the largest market share during the forecast period due to their foundational role in research, diagnostics, and therapeutic development. These products include nucleases, guide RNAs, delivery systems, and validation tools used across academic, clinical, and commercial labs. Demand is rising for high-fidelity enzymes, customizable libraries, and scalable reagent formats. Vendors are offering modular kits tailored to cell type, organism, and editing workflow. Integration with automation platforms and cloud-based design tools is improving throughput and reproducibility.

The academic & research institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the academic & research institutes segment is predicted to witness the highest growth rate as universities and public labs expand CRISPR programs across basic science and translational medicine. Institutions are launching genome engineering centers, collaborative consortia, and open-access toolkits to accelerate innovation. Funding from government agencies and philanthropic organizations is supporting early-stage research and proof-of-concept studies. Academic labs are driving breakthroughs in delivery, specificity, and multiplexing that feed into commercial pipelines. Partnerships with biotech firms and CROs are enabling clinical trial readiness and IP licensing.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced biotech infrastructure, regulatory engagement, and academic excellence. The United States hosts the largest concentration of CRISPR startups, research institutions, and clinical trial sponsors. NIH and DARPA funding is supporting platform innovation and therapeutic validation across rare and complex diseases. FDA guidance on gene editing therapies is improving clarity and accelerating approvals. Canada is scaling translational research and public-private partnerships across genomics and regenerative medicine. These factors are boosting North America's leadership in CRISPR-based therapeutic development.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as genomic medicine, academic investment, and translational infrastructure converge. Countries like China, Japan, South Korea, and India are expanding CRISPR research across agriculture, diagnostics, and human therapeutics. Government-backed programs are funding genome editing centers, biomanufacturing hubs, and clinical trial networks. Local firms are launching region-specific therapies tailored to population genetics and disease burden. Academic institutions are publishing high-impact research and collaborating with global biotech leaders.

Key players in the market

Some of the key players in CRISPR Gene Editing Therapies Market include CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Beam Therapeutics Inc., Caribou Biosciences, Inc., Mammoth Biosciences, Inc., Scribe Therapeutics, Inc., Graphite Bio, Inc., Tessera Therapeutics, Inc., eGenesis, Inc., Verve Therapeutics, Inc., Sherlock Biosciences, Inc., Metagenomi, Inc., ToolGen, Inc. and Cellectis S.A.

Key Developments:

In September 2025, Editas Medicine officially selected EDIT-401 as its lead in vivo development candidate, signaling a strategic pivot toward cardiometabolic applications. The company emphasized its focus on durable, single-dose therapies using optimized CRISPR/Cas9 delivery platforms.

In May 2025, CRISPR Therapeutics entered a multi-target strategic collaboration with Sirius Therapeutics to co-develop and co-commercialize long-acting siRNA programs (notably SRSD107), committing upfront cash and equity investments and agreeing to a cost/profit sharing and regional commercialization split.

Products Covered:

  • CRISPR Kits & Reagents
  • CRISPR Plasmids & Vectors
  • Design & Customization Tools
  • Gene Editing Platforms & Software
  • Contract Research & Manufacturing Services (CRO/CMO)
  • Gene Synthesis & Sequencing Services
  • Gene Expression Analysis Tools
  • Other Products

Applications Covered:

  • Therapeutic Development
  • Drug Discovery & Screening
  • Functional Genomics
  • Stem Cell & Regenerative Medicine
  • Precision Medicine / Personalized Therapy
  • Immunotherapy Development
  • Gene Therapy Clinical Trials
  • Pharmacogenomics
  • Target Validation
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Hospitals & Specialty Clinics
  • Government & Regulatory Bodies
  • Diagnostics Companies
  • Biomanufacturing Firms
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global CRISPR Gene Editing Therapies Market, By Product

  • 5.1 Introduction
  • 5.2 CRISPR Kits & Reagents
  • 5.3 CRISPR Plasmids & Vectors
  • 5.4 Design & Customization Tools
  • 5.5 Gene Editing Platforms & Software
  • 5.6 Contract Research & Manufacturing Services (CRO/CMO)
  • 5.7 Gene Synthesis & Sequencing Services
  • 5.8 Gene Expression Analysis Tools
  • 5.9 Other Products

6 Global CRISPR Gene Editing Therapies Market, By Application

  • 6.1 Introduction
  • 6.2 Therapeutic Development
    • 6.2.1 Rare Genetic Disorders
    • 6.2.2 Oncology
    • 6.2.3 Hematologic Diseases
    • 6.2.4 Infectious Diseases
  • 6.3 Drug Discovery & Screening
  • 6.4 Functional Genomics
  • 6.5 Stem Cell & Regenerative Medicine
  • 6.6 Precision Medicine / Personalized Therapy
  • 6.7 Immunotherapy Development
  • 6.8 Gene Therapy Clinical Trials
  • 6.9 Pharmacogenomics
  • 6.10 Target Validation
  • 6.11 Other Applications

7 Global CRISPR Gene Editing Therapies Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical & Biotech Companies
  • 7.3 Academic & Research Institutes
  • 7.4 Hospitals & Specialty Clinics
  • 7.5 Government & Regulatory Bodies
  • 7.6 Diagnostics Companies
  • 7.7 Biomanufacturing Firms
  • 7.8 Other End Users

8 Global CRISPR Gene Editing Therapies Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 CRISPR Therapeutics AG
  • 10.2 Editas Medicine, Inc.
  • 10.3 Intellia Therapeutics, Inc.
  • 10.4 Beam Therapeutics Inc.
  • 10.5 Caribou Biosciences, Inc.
  • 10.6 Mammoth Biosciences, Inc.
  • 10.7 Scribe Therapeutics, Inc.
  • 10.8 Graphite Bio, Inc.
  • 10.9 Tessera Therapeutics, Inc.
  • 10.10 eGenesis, Inc.
  • 10.11 Verve Therapeutics, Inc.
  • 10.12 Sherlock Biosciences, Inc.
  • 10.13 Metagenomi, Inc.
  • 10.14 ToolGen, Inc.
  • 10.15 Cellectis S.A.

List of Tables

  • Table 1 Global CRISPR Gene Editing Therapies Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global CRISPR Gene Editing Therapies Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global CRISPR Gene Editing Therapies Market Outlook, By CRISPR Kits & Reagents (2024-2032) ($MN)
  • Table 4 Global CRISPR Gene Editing Therapies Market Outlook, By CRISPR Plasmids & Vectors (2024-2032) ($MN)
  • Table 5 Global CRISPR Gene Editing Therapies Market Outlook, By Design & Customization Tools (2024-2032) ($MN)
  • Table 6 Global CRISPR Gene Editing Therapies Market Outlook, By Gene Editing Platforms & Software (2024-2032) ($MN)
  • Table 7 Global CRISPR Gene Editing Therapies Market Outlook, By Contract Research & Manufacturing Services (CRO/CMO) (2024-2032) ($MN)
  • Table 8 Global CRISPR Gene Editing Therapies Market Outlook, By Gene Synthesis & Sequencing Services (2024-2032) ($MN)
  • Table 9 Global CRISPR Gene Editing Therapies Market Outlook, By Gene Expression Analysis Tools (2024-2032) ($MN)
  • Table 10 Global CRISPR Gene Editing Therapies Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 11 Global CRISPR Gene Editing Therapies Market Outlook, By Application (2024-2032) ($MN)
  • Table 12 Global CRISPR Gene Editing Therapies Market Outlook, By Therapeutic Development (2024-2032) ($MN)
  • Table 13 Global CRISPR Gene Editing Therapies Market Outlook, By Rare Genetic Disorders (2024-2032) ($MN)
  • Table 14 Global CRISPR Gene Editing Therapies Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 15 Global CRISPR Gene Editing Therapies Market Outlook, By Hematologic Diseases (2024-2032) ($MN)
  • Table 16 Global CRISPR Gene Editing Therapies Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 17 Global CRISPR Gene Editing Therapies Market Outlook, By Drug Discovery & Screening (2024-2032) ($MN)
  • Table 18 Global CRISPR Gene Editing Therapies Market Outlook, By Functional Genomics (2024-2032) ($MN)
  • Table 19 Global CRISPR Gene Editing Therapies Market Outlook, By Stem Cell & Regenerative Medicine (2024-2032) ($MN)
  • Table 20 Global CRISPR Gene Editing Therapies Market Outlook, By Precision Medicine / Personalized Therapy (2024-2032) ($MN)
  • Table 21 Global CRISPR Gene Editing Therapies Market Outlook, By Immunotherapy Development (2024-2032) ($MN)
  • Table 22 Global CRISPR Gene Editing Therapies Market Outlook, By Gene Therapy Clinical Trials (2024-2032) ($MN)
  • Table 23 Global CRISPR Gene Editing Therapies Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 24 Global CRISPR Gene Editing Therapies Market Outlook, By Target Validation (2024-2032) ($MN)
  • Table 25 Global CRISPR Gene Editing Therapies Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global CRISPR Gene Editing Therapies Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global CRISPR Gene Editing Therapies Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 28 Global CRISPR Gene Editing Therapies Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 29 Global CRISPR Gene Editing Therapies Market Outlook, By Hospitals & Specialty Clinics (2024-2032) ($MN)
  • Table 30 Global CRISPR Gene Editing Therapies Market Outlook, By Government & Regulatory Bodies (2024-2032) ($MN)
  • Table 31 Global CRISPR Gene Editing Therapies Market Outlook, By Diagnostics Companies (2024-2032) ($MN)
  • Table 32 Global CRISPR Gene Editing Therapies Market Outlook, By Biomanufacturing Firms (2024-2032) ($MN)
  • Table 33 Global CRISPR Gene Editing Therapies Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.